Works (2)
Updated: August 4th, 2023 15:35
2013 journal article
Evaluation of the clinical use of tepoxalin and meloxicam in cats
JOURNAL OF FELINE MEDICINE AND SURGERY, 15(8), 678–690.
MeSH headings : Animals; Anti-Inflammatory Agents, Non-Steroidal / therapeutic use; Cat Diseases / drug therapy; Cats; Female; Male; Meloxicam; Pyrazoles / adverse effects; Pyrazoles / therapeutic use; Retrospective Studies; Thiazines / adverse effects; Thiazines / therapeutic use; Thiazoles / adverse effects; Thiazoles / therapeutic use
TL;DR:
Tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study, and several statistically significant changes for serum biochemistry and hematology parameters were within normal limits.
(via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being
(Web of Science; OpenAlex)
Sources: Web Of Science, ORCID, NC State University Libraries
Added: August 6, 2018
2012 journal article
Sustained-Release Celecoxib from Incubated Acrylic Intraocular Lenses Suppresses Lens Epithelial Cell Growth in an Ex Vivo Model of Posterior Capsule Opacity
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 28(4), 359–368.
MeSH headings : Animals; Cataract Extraction; Celecoxib; Corneal Opacity / pathology; Corneal Opacity / prevention & control; Cyclooxygenase 2 Inhibitors / administration & dosage; Cyclooxygenase 2 Inhibitors / pharmacokinetics; Cyclooxygenase 2 Inhibitors / therapeutic use; Delayed-Action Preparations; Dogs; Epithelial Cells / drug effects; Epithelium / drug effects; Epithelium / growth & development; In Vitro Techniques; Lens, Crystalline / cytology; Lens, Crystalline / drug effects; Lens, Crystalline / growth & development; Lenses, Intraocular; Polymethyl Methacrylate; Posterior Capsule of the Lens / cytology; Posterior Capsule of the Lens / drug effects; Posterior Capsule of the Lens / pathology; Postoperative Complications / pathology; Postoperative Complications / prevention & control; Pyrazoles / administration & dosage; Pyrazoles / pharmacokinetics; Pyrazoles / therapeutic use; Sulfonamides / administration & dosage; Sulfonamides / pharmacokinetics; Sulfonamides / therapeutic use
TL;DR:
A 4-day treatment of LCs with a concentration of 20 μM CXB may effectively prevent PCO and further studies are needed to determine whether C XB-incubated IOLs can effectively prevent the development of PCO in vivo.
(via Semantic Scholar)
europepmc.org (repository)
Sources: Web Of Science, NC State University Libraries
Added: August 6, 2018
Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.
Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
